Figure 1.

Engineering effective decoy vesicles requires evaluating key design choices. Human cells may be engineered to release EVs that neutralize virus and inhibit infection. Here, we investigate important open questions as to how general design choices influence the efficacy of decoy vesicle‐mediated inhibition of SARS‐CoV‐2 infection and to what extent this inhibition is robust to mutations that could confer viral escape.